Clinical Trial Update: Combination of Osemitamab (TST001), Pembrolizumab and Chemotherapy as First-line Therapy in Advanced or Metastatic GC/GEJ Adenocarcinoma [Phase 3]

View source ↗

Summary

This clinical trial update describes a Phase 3 study evaluating a triplet regimen of Osemitamab (TST001), pembrolizumab, and chemotherapy as first-line treatmen…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Cancer

Drugs mentioned

• Osemitamab (osemitamab)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Suzhou Transcenta Therapeutics Co., Ltd. | Conditions: Gastric Cancer, Gastroesophageal-junction Cancer | Phase 3 | Status: NOT_YET_RECRUITING